SkinBioTherapeutics Cash Flow Statement

Financials in millions GBP. Fiscal year is July - June.

Millions GBP. Fiscal year is Jul - Jun.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2019
Period Ending	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020	2016 - 2019
Net Income	-2.88	-2.84	-2.79	-1.43	-1.5	Upgrade
Depreciation & Amortization	0.18	0.05	0.04	0.01	0.01	Upgrade
Stock-Based Compensation	-	0	0.05	0.06	0.16	Upgrade
Other Operating Activities	0.15	0.08	-0.08	-0.07	0.09	Upgrade
Change in Accounts Receivable	0.17	-0.05	0.13	-0.2	0.17	Upgrade
Change in Inventory	0.1	0.09	-0.12	-	-	Upgrade
Change in Accounts Payable	-0.44	0.02	0.1	0.07	0.18	Upgrade
Operating Cash Flow	-2.73	-2.65	-2.67	-1.56	-0.89	Upgrade
Capital Expenditures	-0.01	-0.09	-	-	-	Upgrade
Sale (Purchase) of Intangibles	-0.17	-0.08	-0.1	-0.11	-0.07	Upgrade
Other Investing Activities	-2.11	0	-	-0	-	Upgrade
Investing Cash Flow	-2.3	-0.17	-0.1	-0.11	-0.07	Upgrade
Short-Term Debt Issued	1.47	-	-	-	-	Upgrade
Total Debt Issued	1.47	-	-	-	-	Upgrade
Long-Term Debt Repaid	-0.04	-0.04	-0.04	-0	-	Upgrade
Net Debt Issued (Repaid)	1.43	-0.04	-0.04	-0	-	Upgrade
Issuance of Common Stock	3.12	2.62	-	4.12	-	Upgrade
Other Financing Activities	-0.04	-0.26	-	-	-	Upgrade
Financing Cash Flow	4.51	2.32	-0.04	4.12	-	Upgrade
Net Cash Flow	-0.51	-0.49	-2.8	2.45	-0.97	Upgrade
Free Cash Flow	-2.74	-2.73	-2.67	-1.56	-0.89	Upgrade
Free Cash Flow Margin	-226.80%	-2071.02%	-3575.44%	-	-	Upgrade
Free Cash Flow Per Share	-0.01	-0.02	-0.02	-0.01	-0.01	Upgrade
Cash Interest Paid	0.04	-	-	-	-	Upgrade
Cash Income Tax Paid	-0.18	-0.26	-0.12	-	-0.21	Upgrade
Levered Free Cash Flow	-1.79	-1.86	-1.85	-1.17	-0.48	Upgrade
Unlevered Free Cash Flow	-1.76	-1.85	-1.84	-1.17	-0.48	Upgrade
Change in Net Working Capital	-0.07	-0.14	-0.03	0.19	-0.45	Upgrade

Updated Dec 10, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.